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Accepted 1 October 2019; Published online 5 October 2019AbstractObjectives: To describe the methodological characteristics of mediation analyses (MAs) reported in recent randomized controlled trials
(RCTs) and to propose recommendations on the planning, conduct, and reporting of MAs in practice.
Study Design and Setting: We conducted a systematic review by searching MEDLINE (January 1, 2017, to December 1, 2018) for all
reports of RCTs or secondary analyses of previously published RCTs that reported a MA. Two reviewers independently screened the title,
abstracts, and full texts of the identified reports and extracted the data from the 98 eligible studies.
Results: MAs were nearly always (96%) based on a traditional mediation approach. Most studies did not report a sample size calcu-
lation for the MA (96%) or assess potential treatment-by-mediator interactions (96%). In 53% of studies, mediators and outcomes were
simultaneously measured. In 57% of studies, mediator-mediator and mediator-outcome confounders were adjusted for in the analysis,
although adjustment was often limited to few potential confounders. About 30% of studies discussed the assumptions underlying the MA.
Conclusion: The conduct and reporting of MAs remained quite heterogeneous in practice. Future MAs could benefit from a consensus-
based planning, conduct, and reporting guideline for MA.  2019 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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controlled trial1. Introduction
Mediation analysis (MA) is a very common type of statis-
tical analysis in psychology, sociology, epidemiology, and
medicine [1e3]. Such analysis aims at assessing the relative
magnitude of different pathways and mechanisms by which
an exposure may affect an outcome [1e5]. As an example,
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dard systolic blood pressure treatment on cardiovascular risk
was mediated by an indirect, potentially harmful effect
through too low diastolic blood pressure [6]. If results of this
MA show that the intensive treatment may lead to a diastolic
hypotension, which in turn is associated with unfavorable
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Key findings?
 Mediation analysis (MA) is a very common type of
statistical analysis in psychology, sociology, epide-
miology, and medicine. This type of analysis aims
to discover pathways and mechanisms by which an
exposure may affect an outcome. This review de-
scribes how MA was conducted and reported in
recent randomized controlled trials.
 Reported MAs were mostly based on a traditional
approach. The counterfactual-based approach,
which generalizes the traditional approaches to
nonlinear models and linear models that include in-
teractions, was rarely used in recent clinical
research practice.
 Half of the studies considered adjusting for the
mediator-outcome (M-OC) confounders. The set
of M-OC confounders adjusted for often only con-
sisted of the baseline value of the outcome and of
the mediators.
What this adds to what is known?
 The conduct and reporting of MA are quite hetero-
geneous. This might be related to the complexity
of the methodological literature on mediation and
the lack of practical consensus guidelines for the
conduct and reporting of MA.
What is the implication and what should change
now?
 Future MAs could benefit from a consensus-based
planning, conduct, and reporting of MA guideline.
Hands-on tutorials would be useful to facilitate the
use of counterfactual-based mediation techniques
for the analysis of dichotomous and survival end-
points, common in RCTs.
prescribing intensive medication therapies to manage hy-
pertension in practice [6]. The MA, therefore, is useful to
improve patients’ clinical outcomes.
Themost traditional approaches of mediation date back to
the 1980s and were inspired by the popular articles of Judd
and Kenny [7] and of Baron and Kenny [8] in psychological
research. These first seminal works on mediation proposed a
series of tests of links in the causal chain to assess the pres-
ence of an indirect effect. The proposed tests are conservative
and have limited statistical power because of the unnecessary
requirement of a nonzero ITT effect to investigate mediation
[3,9,10]. Several extensions have beenmade to overcome this
limitation and to provide an effect-size measure for the so-
called direct and indirect effects [3,9,10]. In some of these,
T.-T. Vo et al. / Journal of Clinithe direct effect is estimated as the residual association be-
tween outcome and treatment after regression adjustment
for the mediators [3,4,9]. Its difference with the ITT effect
is then viewed as the indirect effect of treatment. In other ex-
tensions, the indirect effect (with respect to a singlemediator)
is calculated as the product of the ITT effect on the mediator
times the residual association between outcome andmediator
after regression adjustment for treatment assignment
[3,4,9,11]. These so-called difference- and product-of-
coefficient methods are equivalent and justified when both
models for the outcome andmediator are linear with no inter-
action. They differ and raise validity concerns when one or
both of these models is/are nonlinear [4,5]. For instance,
when a logistic outcome model is used for a binary endpoint,
then the difference-of-coefficient approach has a systematic
tendency to find indirect effects in settings where treatment
has no effect on mediator; the product-of-coefficient
approach instead delivers direct and indirect effects which
may not add up to the total causal effect, thereby failing to
provide an effect decomposition [4,5]. To accommodate this,
a counterfactual-based framework to MA has recently been
introduced,which has the aforementioned approaches as spe-
cial cases [1,4,5,12]. The literature on this framework is often
of a more technical nature, partly because of its focus on
nonlinear models and partly because it makes more explicit
the unverifiable assumptions on which an MA relies. For
instance, when there are multiple mediators, the
counterfactual-based approaches havemade clear that the ef-
fects along specific sequences of mediators are not identified
withoutmaking strong biological andmodeling assumptions,
although such effects may be seemingly simple to calculate
in the traditional approaches [4,13]. The counterfactual ap-
proaches have moreover emphasized the need to adjust for
mediator-mediator (M-M) confounders in the analysis [14]
(although it should be noted that the estimation of certain
pathways in the traditional approaches and specific counter-
factual extensions thereof is immune to such confounding)
[15]. Regardless of the approach used, the correct temporal
order between the mediators and the outcome, as well as
adjustment for mediator-outcome (M-OC) confounders, is
of critical importance for a valid mediation finding, even
when based on data from an randomized controlled trial
(RCT) [7,10,14].
In this study, we aimed to (i) describe how MAwas con-
ducted and reported in recent RCTs and to (ii) propose rec-
ommendations for the planning, conduct, and reporting of
MAs in future RCTs.2. Methods
2.1. Study design
We conducted a methodological systematic review and
followed the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines [16]. The
80 T.-T. Vo et al. / Journal of Clinical Epidemiology 117 (2020) 78e88protocol was not registered in The International Prospective
Register of Systematic Reviews as this review does not
contain direct health-related outcomes [17].
2.2. Information sources and search strategy
As the primary aim of this review was to describe the
current practice in conducting and reporting MA in clinical
research, we restricted the search strategy to only include
recent reports published on MEDLINE (accessed through
PubMed) over the last 2 years (i.e., from January 1, 2017,
to December 1, 2018, search date: December 11, 2018).
The full search strategy is presented in Appendix 1.
2.3. Eligibility criteria
We included all reports of RCTs and the secondary an-
alyses of previously published RCTs that conducted a
MA to investigate the role of one or more mediators in ex-
plaining the pathway from treatment to a specific health
outcome. We excluded non-English publications, articles
for which full texts were unavailable, and protocols and
RCTs in which an MA was conducted, but not to explain
the effectiveness of the randomly assigned treatment. For
instance, studies were excluded if their data were used to
investigate the mediated effect of an exposure that was
not the randomized treatment.
2.4. Study selection
We exported the references retrieved from the search
into an MS Excel document (Microsoft Corp). Two re-
viewers (T.-T.V. and C.S.) independently screened the titles
and abstracts of all retrieved references to identify the
eligible reports. The full-text copies of potentially eligible
reports were also obtained and independently examined
for further assessment if needed. In the case of disagree-
ment, consensus was determined by a discussion between
the two reviewers. The result of this process was reported
through a PRISMA flowchart [16].
2.5. Data extraction
A data-extraction form was designed, pilot-tested, and
refined by a reviewer (T.-T.V.) to extract the following in-
formation from the eligible reports: (i) the number of medi-
ators investigated; (ii) the method used to assess the
indirect treatment effect through the mediators; (iii) the
methodological characteristics of the reported MA; and
(iv) the discussion of authors regarding the assumptions un-
derlying the method being used (see Appendix 2 for the
data-extraction form).
For item 2 in the aforementioned list, we classified the
methods used to assess mediation into two groups, namely
(i) traditional approaches (including the Baron and Kenny’s
framework, the difference- and product-of-coefficient ap-
proaches) and (ii) counterfactual-based approaches(Table 1). When multiple mediators were assessed, we
further reported whether the different mediators were
included in the analysis in a parallel or serial manner
(Table 1). If a parallel MAwas considered, we investigated
whether the (parallel) mediators were assessed simulta-
neously in the same model or separately in different
models. We made this distinction because the use of sepa-
rate MAs, each involving a single mediator, is arguably
invalid (see further discussion in Appendix 3 and [14]).
The use of different approaches was also stratified based
on the outcome type (continuous, binary, time-to-event, or
others) and the outcome model used.
For item 3, we determined whether the eligible studies (i)
reported a sample size calculation for the MA or commented
on the impact of the sample size on the MA results, (ii) con-
ducted a complete-case analysis or considered an alternative
approach to handle the missing data, (iii) included or evalu-
ated the potential of treatment-mediator interaction(s), (iv)
considered confounding adjustment for the M-M and M-
OC relationships, (v) considered the statistical significance
of the ITT treatment effect as a condition to investigatemedi-
ation, (vi) conducted sensitivity analysis to assess the impact
of the mediators’ measurement error, and (vii) reported the
goodness of fit (i.e., statistics that describe how well a model
fits the set of observations) of the mediator(s) and outcome
models. For item 4, when the authors reported confounding
adjustment but did not clearly state whether it was for the
mediator or for the outcome model, we assumed that the au-
thors at least considered covariate adjustment in the outcome
model. The latter is desirable because adjustment for covari-
ates in themediatormodel is less important when treatment is
randomized.
For item 4, we determined whether authors discussed the
assumptions that underlined the MA and which assumptions
were discussed. We extracted the exact assumptions being
discussed using open-ended questions. We did not assess
the interpretation of the clinical impact of themediation find-
ings. For instance, when a statistically significant mediation
finding was found, the authors often discussed how such
finding would be useful in medical practice (e.g., in patient
management). We did not assess such discussion.
When several MAs were conducted for several outcomes
of interest, we focused only on the analysis of the primary
outcome. A second reviewer (C.S.) independently double-
checked 25% of the extracted articles. In case of disagree-
ment, consensus was determined by a discussion between
the two reviewers (T.-T.V. and C.S.).2.6. Data synthesis
Categorical data were summarized using frequencies
and percentages. Continuous data were summarized using
median and interquartile range. We reported the overall
findings and stratified them based on the number of medi-
ators investigated (i.e., single and multiple mediators). Data
were analyzed using MS Excel 2010.
Table 1. Classification of mediation analysis methodology in clinical research
Methods Basic properties
Traditional approachesa
Single mediator
 Different regression models are specified for the mediator and the outcome.
For instance:
EðY jXÞ5 c0 þ cXþ c1C
EðMjXÞ5 a0 þ aXþ aC
EðY jX;M;CÞ5 b0 þ b1Xþ b2Cþ bM
 In the BK approach, a series of test of links in a causal chain is specified to assess the null hypothesis
of no indirect effect (IE). No estimators of the direct effect (DE) and IE are proposed.
 In other traditional approaches, the IE of X on Y through M is quantified as the product ab. The DE of X
on Y is calculated as c
0
5c ab [3,7,8,10]. These identities hold when all models are linear without
treatment-mediator interaction (see appendix 5 and [4,18,19]).
 The difference-of-coefficient approach assesses the null hypothesis of no IE by using statistics linked
to the difference c c0. The product-of-coefficient approach assesses the null hypothesis by using
statistics linked to the product ab. The underlying assumptions and the performance of these tests are
discussed elsewhere [9].
Counterfactual approachesb
Single mediator
 Different, possibly nonlinear, regression models are specified for the mediator and the outcome.
 The IE of X on Y through M is quantified by using the aforementioned models to simulate (via Monte
Carlo simulation) how a change in X would affect M for each individual, how this change would in turn
affect Y, and then averaging these results [1,18].
 The DE of X on Y is quantified by using the aforementioned models to simulate (via Monte Carlo
simulation) how Y would change for each individual if X were changed, but M were fixed at the
(simulated) level it would take if X took on some reference level, and then averaging these results
[1,18].
Parallel mediators  Using a regression model for Y which includes X, C, and all mediators, and separate models for each
mediator which include X and C.
 In the traditional approaches, the individual IE for mediator i is aibi and the total IE for a model
including 2 mediators is a1b1 þ a2b2, with bi being the effect of mediator i on outcome and ai the effect
of exposure on mediator i. In the counterfactual approaches, Monte Carlo simulation is used [3,14,15].
 These approaches can correctly infer the effect along the combination of all pathways from X to Mi
(along all possible paths) and further from Mi to Y (directly), even when the mediators are correlated,
but not when separate analyses are considered with one mediator at a time [14].
Serial or sequential mediation  Assuming a causal relationship from one mediator to the other.
 In the traditional approaches, IEs through different pathways are quantified as different product of
coefficients, e.g., the IE through M1 then M2 is a1cb2. In the counterfactual approaches, Monte Carlo
simulation is sequentially used with respect to different blocs of mediators [3,14].
 These approaches are sensitive to misspecification of the causal order between mediators and to the
presence of unmeasured common causes of the mediators.
 The traditional approaches have the drawback of enabling one to calculate IEs along all possible paths
(e.g., through M1 then M2), even though some necessitate overly strong assumptions [13,15].
Abbreviations: X, the randomized treatment; Y, the outcome of interest; M and Mi, the potential mediator(s); C, the confounders of mediator-
mediator/outcome relationship; IE, indirect effect; BK, Baron and Kenny.
a Including the Baron and Kenny framework and the product- and difference-of-coefficient approaches.
b Other causal approaches, e.g., the stochastic mediation approaches [20], have not been reviewed here.
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Based on the results of this systematic review, we proposed
practical recommendations for the planning, conduct, and re-
porting of futureMAs in clinical research.We consulted other
textbooks and methodological reviews on MAs to assure the
completeness of these recommendations [4,18,19,21e23].3. Results
3.1. General characteristics of eligible studies
The PRISMA flow diagram summarizing the screening
process is given in Fig. 1. Of 197 references identified,99 reports were excluded for the following reasons: not
an RCT (n5 39), no MA conducted (n5 41), trial protocol
(n 5 8), conducted MA not for explaining the effect of the
randomized treatment (n 5 10), non-English article (n 5 1)
(Appendix 3).
Among the 98 eligible studies, 48.0% (n 5 47) were
RCT reports and 52.0% (n 5 51) were secondary analyses
of previously published RCTs (Appendix 4). In 68.4% of
studies (n 5 67), multiple mediators were investigated.
The outcome and mediator being assessed were continuous
in 84.7% (n 5 83) and 92.9% (n 5 91) of studies, respec-
tively. In 53.1% of studies (n 5 52), the mediators and
outcome were measured at the same time point, which
might carry an additional risk of bias because of the lack
Records identified through database searching 
(n = 197) 
Records after duplicates removed 
(n = 197) 
Records screened 
(n =197) 
Records excluded (n = 99) 
• Not an RCT (n = 39) 
• No mediation analysis 
conducted (n = 41) 
• Trial protocol (n = 8) 
• Mediation analysis not for 
explaining the randomized 
treatment effect (n = 10) 
• Non-English paper (n = 1) 
Full-text articles assessed for 
eligibility 
(n =98)
Full-text articles excluded, with 
reasons 
(n =0)
Studies included in 
quantitative synthesis  
(n = 98)
Fig. 1. e Study selection PRISMA Flowchart. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomized
controlled trial.
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[7,8,10,24,25]. Other characteristics of the eligible reports
are summarized in Table 2. In data extraction, the Kappa
coefficient equaled 0.86 (Appendix 2).
3.2. Methods used to investigate mediation
Among studies assessing a single mediator, the tradi-
tional approaches were applied in 90.3% of cases
(n 5 28). Counterfactual-based MA approaches, in
contrast, were considered in two studies (6.5%). In one
study (3.2%), both frameworks were used.
The traditional approaches were applied in 98.5% of
studies assessing multiple mediators (n 5 66). Among
these, 88.1% (n 5 59) considered a parallel MA, with
37.3% (n 5 25) considering one common analysis for all
mediators, 38.8% (n 5 26) considering separate analyses
for separate mediators, and 11.9% (n 5 8) considering a
two-step approach. In the two-step approach, the mediators
were first separately analyzed. The ones showing statistical
significance for the indirect effect in this step (or allmediators) were then taken forward to the second step,
where one common (final) model was fitted (Table 3).
The traditional approaches were frequently used across
all types of outcome. Among 11 studies with a binary or
time-to-event outcome, seven studies (63.6%) applied the
traditional approaches based on a logistic or Cox regression
model (Table 3).
3.3. Methodological characteristics of the reported MA
Only 4.1% of studies (n 5 4) reported on the evaluation
of potential interaction between the treatment and the me-
diator(s) on the outcome (Table 4). Two studies included
the interaction in the final MA and two others did not
because of the lack of statistical significance.
Sample size calculation for MA was considered in
4.1% of studies (n 5 4). A complete-case analysis was
conducted by 50.7% of studies (n 5 34), with 19.4%
(n 5 13) considering some covariate adjustment to cor-
rect for imbalance between treatment groups because of
missing data.
Table 2. Characteristics of the eligible studies
Characteristics Statistics
Study design, n (%)
Original research report of an RCT 47 (48.0)
Reporting information on protocol
registration
19 (19.4)
Secondary analysis of a previous RCT 51 (52.0)
Number of randomized patients,
median (IQR)
163 (100e362)
Type of intervention, n (%)
Medication 7 (7.1)
Psychological, cognitive, behavioral
intervention (including training,
education, counseling with or
without other components)
79 (80.6)
Simulations of different contexts 3 (3.1)
Decision aid booklets 2 (2.0)
Others 7 (7.1)
Target condition, n (%)
Addiction and behavioral medicine 39 (39.8)
Mental health disorders
(without other conditions)
29 (29.6)
Oncology 10 (10.2)
Diabetes and obesity 7 (7.1)
Musculoskeletal diseases 6 (6.1)
HIV and infectious diseases 3 (3.1)
Cardiovascular diseases 2 (2.0)
Others 2 (2.0)
Primary outcome, n (%)
Behaviors and affects (e.g., self-esteem,
alcohol consumption, decision making,
social connection, pain intensity,
and so forth)
57 (58.2)
Symptoms of mental disorders (stress,
suicide, depression, and so forth)
23 (23.5)
Biological concentration 2 (2.0)
Cardiovascular risk 3 (3.1)
Physical functionality 2 (2.0)
Others 11 (11.2)
Number of mediators investigate, n (%) 2 (1e4)
Single mediator 31 (31.6)
Multiple mediator 67 (68.4)
Mediator type, n (%)
Continuous variablea 91 (92.9)
Binary variablea 5 (5.1)
Ordinal variablea 1 (1.0)
Unclear 1 (1.0)
Outcome type, n (%)
Continuous variable 83 (84.7)
Binary variable 8 (8.2)
Count variable 4 (4.1)
Survival variable 3 (3.1)
Dataset, n (%)
(Continued )
Table 2. Continued
Characteristics Statistics
Cross-sectional (mediator(s) and
outcome measured at the
same time)
52 (53.1)
Longitudinal (mediator(s) measured
before outcome)
46 (46.9)
Abbreviations: RCT, randomized controlled trial; IQR, interquartile
range; HIV, human immunodeficiency virus.
a Number of studies investigating each type of mediators (Media-
tors of different types, e.g., binary and continuous, were not evaluated
in any studies.).
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considered by 57.1% of studies (n 5 56). Such adjustment
was less common among studies assessing a single medi-
ator (48.4%, n 5 15). Among studies considering M-M
and M-OC adjustments (n 5 56), 32.1% (n 5 18) only
adjusted for the baseline value of the outcome and/or me-
diator(s) of interest. The remaining 67.9% (n 5 38) also
adjusted for other baseline characteristics, with a total
number of adjusted covariates (already including baseline
levels of the mediator and/or outcome) ranging from 2 to
7 (IQR). No studies considered adjustment for postran-
domization confounding factors of the M-OC association
(Table 4).
Information on the goodness of fit of the models used in
the MA was reported in 27.6% of studies (n 5 27). In
11.2% of studies (n 5 11), authors stated that a statistically
significant ITT effect was considered as a prior condition to
investigate mediation. Concerns over mediator(s)’ measure-
ment error due to the use of self-reported data were ex-
pressed in 35.7% of studies (n 5 35), but no studies
considered a sensitivity analysis to further assess these
(Table 4).3.4. Discussion on the MA
In 29.6% of the eligible studies (n 5 29), the authors
discussed the plausibility of different assumptions under-
lying the MA. The assumption of no unmeasured M-M
and M-OC confounders was discussed in 9.2% (n 5 9)
of studies. The assumption of no treatment-induced con-
founders of the M-OC relationship was discussed in
2.0% of studies (i.e., two studies using counterfactual-
based approaches). Concerns about the temporal order
of the mediator(s) and the outcome were expressed in
19.4% (n 5 19) of studies, with a reversed MA (i.e.,
switching the role of the outcome and the mediators in
the analysis) conducted in 6.1% (n 5 6) of studies. Con-
cerns about potential misspecification of the mediator(s)/
outcome models were expressed in 3.1% (n 5 3) of
studies (Table 4).
Recommendations on the planning, conduct, and report-
ing of future MAs are reported in Table 5.
Table 3. Framework used for the mediation analysis reported in the eligible studies
Item Single mediator (N [ 31) Multiple mediators (N [ 67) Overall (N [ 98)
Method used, n (%)
Traditional approaches 28 (90.3) - -
Counterfactual-based approaches 2 (6.5) - -
Both traditional and causal approaches 1 (3.2) - -
Traditional approaches: parallel mediators - 59 (88.1)a -
One separate model for each mediator - 26 (38.8) -
One common model for all mediators - 25 (37.3) -
Two-step analysisb - 8 (11.9) -
Traditional approaches: serial mediators - 9 (13.4)a -
Counterfactual-based approaches, one
model for each mediator
- 1 (1.5) -
Method used, stratified by outcome, n (%)
Continuous outcome 26 (83.9) 57 (85.1) 83 (84.7)
Traditional approaches 26 (83.9) 56 (83.6) 82 (83.7)
Counterfactual-based approaches 0 (0.0) 1 (1.5) 1 (1.2)
Binary outcome 3 (9.7) 5 (7.5) 8 (8.2)
Logistic regression, traditional approaches 0 (9.7) 4 (6.0) 4 (4.1)
Log-linear regression, traditional approaches 0 (9.7) 1 (1.5) 1 (1.2)
Logistic regression, counterfactual-based approaches 3 (9.7) 0 (0.0) 3 (3.1)
Time-to-event outcome 1 (3.2)c 2 (3.0) 3 (3.1)
Cox regression, traditional approaches 1 (3.2)c 2 (3.0) 3 (3.1)
Cox regression, counterfactual-based approaches 1 (3.2)c 0 (0.0) 1 (1.2)
Count outcome, log-linear regression, traditional approaches 1 (3.2) 3 (4.5) 4 (4.1)
Abbreviations: MA, mediation analysis; IE, indirect effect.
a Two studies considered both parallel and serial MA.
b One separate analysis for each mediator (step 1), then a common analysis for the mediators with significant IE in the previous step or all
mediators (step 2).
c Same study with both approaches used.
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MA is a statistical technique that has become increas-
ingly popular over the past decade [1e3]. In this methodo-
logical systematic review, we evaluated how MA was
conducted and reported in recently published RCTs.
Several remarks can be highlighted. First, our review
confirmed that M-OC confounding adjustment was being
considered in recent MAs of RCTs. However, the con-
founders taken into account were often only the baseline
value of the outcome and of the mediator(s). Adjusting
for a wider collection of confounders of the M-M and M-
OC relationship, which may in particular include con-
founders that are themselves mediators, should be more
encouraged in practice to strengthen the validity of the find-
ings [19]. Besides, baseline covariate adjustment is addi-
tionally important whenever a complete-case analysis is
adopted, as it may help to adjust for selection bias origi-
nating from imbalances between the treatment groups due
to the exclusion of some patients from the analysis.
Regardless of the methods being used, MA is often
based on quite strong assumptions [3,19]. These assump-
tions should be discussed to avoid any misinterpretation
of the findings. As the page restriction policies of mostjournals may discourage researchers to do this, supple-
mental discussions should be encouraged in online Web
appendices. Alternatively, journal editors should also
consider providing more space for consideration of the as-
sumptions described in the article.
Most MAs assessed in this review were only conducted
secondarily after the end of the main trial. Planning MAs in
advance (e.g., in the trial protocol) can help to handle some
methodological challenges that remained unaddressed in
most current studies, for example, the sample size calcula-
tion, the measurement of key confounders, the quantifica-
tion of measurement error in the mediators, and the
prevention of missing data in key (mediator) variables.
Finally, counterfactual mediation approaches were
rarely used in recent clinical research practice. This is prob-
ably because these approaches have only become available
within the last 20 years, with the literature often being high-
ly technical. The relatively small number of articles that re-
ported on MAs of dichotomous and survival endpoints, in
spite of these endpoints being common in RCTs, may also
be due to a lack of familiarity with (counterfactual) media-
tion approaches for such endpoints. More detailed instruc-
tions (e.g., via hand-on tutorials) are hence needed to
further promote the use of these approaches as they
Table 4. Characteristics of the mediation analyses reported in the eligible studies
Item Single mediator (N [ 31) Multiple mediators (N [ 67) Overall (N [ 98)
Methodological characteristics
SS calculation, n (%)
Calculating an SS for the MA 0 (0.0) 4 (6.0) 4 (4.1)
Only discussing the impact of SS on the findings 11 (35.5) 26 (38.8) 37 (37.8)
No information 20 (64.5) 37 (55.2) 57 (58.2)
Handling missing data
ITT analysis, n (%) 9 (29.0) 26 (38.8) 35 (35.7)
Multiple imputation 2 (6.5) 4 (6.0) 6 (6.1)
Single imputation 2 (6.5) 3 (4.5) 5 (5.1)
Last observation carried forward 0 (0.0) 3 (4.5) 3 (3.1)
Full information maximum likelihood 5 (16.1) 13 (19.4) 18 (18.4)
Others 0 (0.0) 3 (4.5) 3 (3.1)
Complete-case analysis, n (%) 20 (64.5) 34 (50.7) 54 (55.1)
Percentage of data excluded, median (IQR) 15 (11e37) 12 (21e36) 19 (11e36)
Not adjusting for T-M confounders, n (%) 13 (41.9) 21 (31.3) 34 (34.7)
Adjusting for T-M confounders, n (%) 7 (22.6) 13 (19.4) 20 (20.4)
Number of adjusted covariates, median (IQR) 4 (3.5e5.5) 4 (2e5) 4 (2e5)
No missing data or nor reported, n (%) 2 (6.5) 7 (10.4) 9 (9.2)
Considering statistically significant ITT treatment
effect as a condition to investigate mediation, n (%)
3 (9.7) 8 (11.9) 11 (11.2)
Evaluating treatment-mediator(s) interaction(s), n (%) 1 (3.2) 3 (4.5) 4 (4.1)
M-M and M-OC confounding adjustment
No adjustment or not reported, n (%) 16 (51.6) 26 (38.8) 42 (42.9)
Only for the baseline value of the outcome
and/or mediator(s), n (%)
2 (6.5) 16 (23.9) 18 (18.4)
Also for other baseline covariates, n (%) 13 (41.9) 25 (37.3) 38 (38.8)
Number of covariates adjusted, n (%)a 4 (3e7) 4 (2e7) 4 (2e7)
Reporting the GOF of the models, n (%) 8 (25.8) 19 (28.4) 27 (27.6)
Discussing the risk of the mediator(s)’ measurement error 8 (25.8) 27 (40.3) 35 (35.7)
Discussion of the underlying assumptions, n (%)
No discussion 19 (61.3) 50 (74.6) 69 (70.4)
Temporal order of mediator(s) and outcomeb 8 (25.8) 11 (16.4) 19 (19.4)
Unmeasured mediator(s)-outcome confounders 4 (12.9) 5 (7.5) 9 (9.2)
Treatment-induced mediator(s)-outcome confounders 2 (6.5) 0 (0.0) 2 (2.0)
Model misspecification 2 (6.5) 1 (1.5) 3 (3.1)
Abbreviations: SS, sample size; ITT, intent-to-treat; T-M, treatment-mediator; M-M, mediator-mediator; M-OC, mediator-outcome; GOF, good-
ness of fit; IQR, interquartile range; MA, mediation analysis.
a The total number of variables adjusted for in the analysis, already including baseline values of the outcome/mediator(s).
b Including the studies considering a reversed mediation analysis.
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and linear models that include treatment-mediator interac-
tions and moreover enable a more refined confounding
control.
Given the heterogeneity in conduct and reporting MA in
clinical research, there is a strong need for a valid,
consensus-based reporting guideline for MA as is
commonly done in other research fields. We hope that the
practical recommendations in Table 5 will serve as a first
step toward such endeavor.
Our findings were in line with results of other MA re-
views, which also outlined the heterogeneity in conductingand reporting MAs in practice [21e23]. However, while the
previous reviews either assessed systematic reviews of MAs
[21] or focused on studies using a particular approach [22]
or a particular type of outcome [23], we here attempted to
give a broader overview on the use of different approaches
in different contexts.
Our study suffered from some limitations. First, we only
considered MEDLINE for the search of eligible trials. This
review is hence not extensive and representative for all tri-
als conducted in the searching period. However, our pri-
mary aim is to provide a description of recent practice
and, hence, to provide insights into important conduct
Table 5. Recommendations on the conduct and reporting of mediation analysis in clinical research
1. Planning
1.1 Whenever possible, plan mediation analyses a priori in the trial protocol to strengthen the validity of the findings.
1.2 Decide on the choice of mediators based on the clinical rationale underlying the mechanisms through which the treatment affects the
outcome, or based on independent data.
1.3 Plan the collection of prerandomization and postrandomization confounders of the M-M and M-OC relationships. Foresee if any of
these confounders is treatment-induced (e.g., collected after the onset of treatment and therefore possibly affected by treatment).
1.4 Measure the mediators before the outcome, and preferably repeatedly, to assure the causal interpretation of the findings [7,8,10,24,25].
1.5 Develop insight by constructing the causal diagram underlying the causal relationship of the treatment, mediator(s), and outcome.
For a practical example, see [4,19,26].
1.6 Estimate the sample size for the MA. For detailed instructions, see [10,27].
1.7 Do not make the conduct of a mediation analysis dependent on whether a statistically significant ITT treatment effect is found.
The ITT effect may be null, even when there is an important indirect effect that is of opposite sign to the remaining direct effect [10,28].
2. Conduct
2.1 Use the multiple imputation approach (or other valid approaches) to handle missing data. When a complete-case analysis is used, adjust
for baseline covariates that are differentially distributed between the treatment groups, as well as between the compleated cases and the non-
completed cases in the study. A sensitivity analysis can also be carried out to assess the impact of different approaches on the findings [10].
2.2 Do not consider separate analyses for separate mediators, even in a parallel MA. Evidence supporting the so-called two-step approach
(which only includes in the final analysis the mediators that are statistically significant when being assessed individually) is also lacking.
2.3 Choose an appropriate framework for the analysis
‒ The Baron and Kenny approach is conservative, has low statistical power than other approaches, and does not propose a proper measure
of the direct and indirect effect [9,11].
‒ The product- and difference-of-coefficient approaches and the counterfactual mediation approaches based on natural direct and indirect
effect coincide in the case of linear models without interactions for mediators and outcome.
‒ Counterfactual-based mediation approaches are more encouraged when treatment-mediator interactions present or when the analysis
involves binary or time-to-event endpoints that necessitate nonlinear models (e.g., logistic and Cox models). [4,5,29]
2.4 Assess potential interaction(s) between treatment and confounding factors, treatment and mediator, mediator and mediator in the
mediator and outcome models. Evaluate the goodness-of-fit of each model.
2.5 Adjust for M-M and M-OC confounders. This is encouraged in both approaches, even in randomized trials and in the absence of
missing data. Indeed, the mediator(s) is/are not manipulated so that M-M and M-OC confounders may present [7,10,14,30].
2.6 If possible, perform sensitivity analysis to assess sensitivity of the results to:
‒ The assumption of no unmeasured M-M/OC confounders [31].
‒ Potential measurement errors of the mediators [19].
2.7 Use apt strategies when some of the M-M/OC confounders are potentially affected by the treatment (e.g., by considering these
confounders as mediators themselves [18]).
3. Reporting
3.1 Report the approaches used for mediation and provide a causal diagram that underlies the analysis.
3.2 Report the sample size calculation, the actual sample size of the MA, and how the missing data are handled.
3.3 Report all confounders considered and adjusted for in the analysis.
3.4 Report the model-building procedure and the final form of all models used in the analysis. Report the goodness-of-fit of these models.
3.5 Report the point estimates and the confidence intervals of the different direct, indirect, and total treatment effects.
3.6 Report the methods and results of all sensitivity and other additional analyses (in the main article or appendices).
3.7 Discuss the validity of all causal assumptions underlying the analysis (in the main article or appendices) [3,19].
Abbreviations: ITT, intent-to-treat; M-M, mediator-mediator; M-OC, mediator-outcome; MA, mediation analysis.
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future practice. Second, the data extraction in this review
was only partially double-checked (25%) by a second
reviewer, which might result in potential mistakes. As the
level of agreement among the two reviewers was relatively
high (86%), the risk of incorrectly extracted data was rela-
tively small. Third, we only considered MAs conducted in
RCTs but not in observational studies, where the concernsabout potential confounding or the temporal order of medi-
ators and outcome are even greater. Fourth, some other as-
pects of the MAwere not evaluated in this review, including
the theoretical justification for the mediators selected and
assessed in the included studies, the implementation of in-
terventions, and the measurement of outcome. In every
article, the authors provided explanation on how and why
they focused on the assessed mediators. However, assessing
87T.-T. Vo et al. / Journal of Clinical Epidemiology 117 (2020) 78e88the appropriateness of this rationale was challenging as it
required knowledge on the topic of interest. Also, we did
not evaluate the implementation of interventions or the
outcome assessment as these are important issues in trials,
but they are not specific to MA. Finally, as most eligible
studies in this review considered linear models and did
not assess or report assessments regarding treatment-
mediator interaction, we could not explore whether the
alternative use of the counterfactual-based approaches
would have been more appropriate.5. Conclusion
The conduct and reporting of MA in recent trials remain
quite heterogeneous. A valid, consensus-based methodolog-
ical guideline is needed to enhance the planning, conduct,
and reporting quality of MA in clinical research.CRediT authorship contribution statement
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